Laura Mariani, MD
Nephrology · Ann Arbor, MINPI 1649333717
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $137,136 of the $149,593 with a category attached, or 91.7%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 62.8% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $118,184 and has fallen 81.9% since, to $21,371 in 2025. Among nephrology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 45 payments — averaging $3324.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$94K
- Travere Therapeutics, Inc.$36K
- Otsuka America Pharmaceutical, Inc.$7K
- Novartis$5K
- Apellis Pharmaceuticals, Inc.$4K
- Calliditas Therapeutics US Inc.$3K
- plus $204 from 2 others
Across 7 payments — averaging $9906.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$32K
- Vertex$29K
- Novartis$8K
What the payments were for
- Consulting fees$137,13692%
- Speaking & faculty fees$7,2005%
- Travel & lodging$3,6532%
- Food & beverage$1,6041%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $93,901 |
| Travere Therapeutics, Inc. | 29 | $35,553 |
| Otsuka America Pharmaceutical, Inc. | 2 | $7,445 |
| Novartis | 2 | $5,375 |
| Apellis Pharmaceuticals, Inc. | 2 | $3,974 |
| Calliditas Therapeutics US Inc. | 4 | $3,141 |
| GSK | 1 | $118 |
| Aurinia Pharma U.S., Inc. | 2 | $86 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TARPEYO$3,125
How this compares
$149,593 in reported general payments places this provider in the 95th percentile of 325 nephrology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Losartan Potassium | 33 | $319 |
| Carvedilol | 17 | $235 |
| Lisinopril | 27 | $157 |
| Allopurinol | 13 | $116 |
| Amlodipine Besylate | 27 | $100 |
| Tamsulosin Hcl | 12 | $86 |
| Famotidine | 12 | $43 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Ann Arbor
- Alexander YevzlinAnn Arbor$1.1M
- Matthias KretzlerAnn Arbor$70K
- Lenar YessayanAnn Arbor$40K
- Bruce RobinsonAnn Arbor$38K
- Karthik RamaniAnn Arbor$27K
- Rajiv SaranAnn Arbor$23K
- Panduranga RaoAnn Arbor$20K
- Andrea OliverioAnn Arbor$15K
- Abhijit NaikAnn Arbor$10K
- Akinlolu OjoAnn Arbor$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.